Cancer of the urinary bladder is the fifth most common neoplasm in the industrialized countries.
Diagnosis and surveillance are dependent on invasive evaluation with cystoscopy and to some degree cytology as an adjunct analysis. Nomuscle invasive bladder cancer is characterized by frequent recurrences after resection, and up to 30% will develop an aggressive phenotype. The journey towards a noninvasive test for diagnosing bladder cancer, in order to replace or extend time between cystoscopy, has been ongoing for more than a decade. However, only a handful of tests that aid in clinical decision making are commercially available. Recent reports of DNA methylation in urine specimens highlight a possible clinical use of this marker type, as high sensitivities and specificities have been shown. This paper will focus on the currently available markers NMP22, ImmunoCyt, and UroVysion as well as novel DNA methylation markers for diagnosis and surveillance of bladder cancer.
Written by:
Reinert T. Are you the author?
Department of Molecular Medicine, Aarhus University Hospital, 8200 Aarhus N, Denmark.
Reference: Adv Urol. 2012;2012:503271.
doi: 10.1155/2012/503271
PubMed Abstract
PMID: 22761614
UroToday.com Investigative Urology Section
